ACTINOGEN MEDICAL LIMITED — Investor Relations & Filings

Actinogen Medical Limited is a clinical-stage company focused on the development of novel therapies for neurological and metabolic diseases associated with chronically elevated cortisol. The company’s lead therapeutic candidate, Xanamem, is a small molecule designed to inhibit the 11β-HSD1 enzyme, which converts inactive cortisone to active cortisol within the brain and peripheral tissues. By reducing intracellular cortisol levels, Xanamem aims to address cognitive impairment and functional decline. The company’s primary clinical programs target Alzheimer’s disease and cognitive impairment associated with depression. Actinogen Medical Limited prioritizes the advancement of its lead candidate through rigorous clinical trials to establish efficacy in improving cognitive performance and managing stress-related neurological conditions.